Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Feb 22, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at different ways to manage pain after skin graft surgery, specifically at the site where the skin is taken from. The study is comparing three methods: Lidocaine, Liposomal Bupivacaine, and a regional nerve block. The goal is to see which option helps reduce pain and the need for opioid medications in patients who have suffered burns covering less than 20% of their body.

To participate in the trial, you need to speak either Spanish or English and have burn injuries that meet specific criteria: less than 20% of your body burned and less than 5% of that being deep burns. If you are pregnant, have chronic pain conditions, or are allergic to local anesthetics like Lidocaine, you won’t be eligible. If you join the study, you’ll receive one of the pain management treatments and be monitored for your pain levels and medication use after the surgery. This research aims to improve pain relief options for patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Spanish/English speaking
• • \<20%TBSA; \<5% TBSA deep partial or full thickness burns
• Exclusion Criteria:
• • chronic pain syndrome
• • \> 20% TBSA burn injury; \> 5% TBSA deep partial or full thickness burn
• • pregnant
• • allergy to lidocaine or other local anesthetics
• • burns to anterior thighs